AlgiPharma was founded in August 2006, based on research and development carried out by FMC BioPolymer AS and the Biopolymer Foundation at the Norwegian University of Science and Technology in Trondheim, Norway.
The company owns or licenses all relevant patents upon which the technology platform and products are developed.
AlgiPharma’s objective is to develop and market selected products and therapies and to license technology and product candidates to suitable partners.
The company is supported by national and international research programs and grants. We work closely with a number of highly recognized academic institutions and research organizations in Europe and USA.
The company is privately owned.
AlgiPharma’s OligoG technology is based on highly purified and defined oligomer structures processed and isolated from the alginate polysaccharide. This unique active ingredient is highly water soluble, with a pronounced negative charge density, and with a strong affinity for multivalent cations. The molecule is stable, non-toxic and bio-compatible.
The OligoG technology is designed and proven to have the following capabilities:
Disruption of microbial biofilms
Potentiation of the effect of antimicrobial compounds
Inherent bacteriostatic properties
Inhibition of bacterial adherence to surfaces